Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 17, 2026
DataAggregated Company Financials
Companies65
  • 7D-3.2%
  • 3M7.5%
  • 1Y11.4%
  • YTD-14.2%

The Life Sciences industry has been flat over the last week, but Thermo Fisher Scientific has lost 4.3%. As for the the longer term, the industry is up 8.8% over the past 12 months. Earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 17 Jun 2026US$585.9bUS$150.6bUS$13.7b40.9x42.7x3.9x
Fri, 15 May 2026US$533.2bUS$150.3bUS$14.0b31.7x38.1x3.5x
Sun, 12 Apr 2026US$561.3bUS$147.8bUS$14.1b37.3x39.8x3.8x
Tue, 10 Mar 2026US$569.0bUS$147.8bUS$14.0b34.7x40.7x3.8x
Thu, 05 Feb 2026US$637.6bUS$146.9bUS$12.6b36.5x50.6x4.3x
Sat, 03 Jan 2026US$658.8bUS$145.8bUS$12.4b36.1x53.3x4.5x
Mon, 01 Dec 2025US$678.1bUS$145.8bUS$12.5b37x54.4x4.7x
Wed, 29 Oct 2025US$656.2bUS$145.3bUS$14.4b32.8x45.5x4.5x
Fri, 26 Sep 2025US$556.8bUS$144.3bUS$14.6b29.8x38.3x3.9x
Sun, 24 Aug 2025US$593.8bUS$144.1bUS$14.5b29.6x41x4.1x
Tue, 22 Jul 2025US$520.6bUS$142.9bUS$9.1b34x57x3.6x
Thu, 19 Jun 2025US$515.8bUS$142.9bUS$9.2b35.2x56.3x3.6x
Sat, 17 May 2025US$508.3bUS$142.7bUS$9.1b33.3x55.9x3.6x
Mon, 14 Apr 2025US$513.8bUS$142.6bUS$10.0b34.6x51.6x3.6x
Wed, 12 Mar 2025US$598.7bUS$143.1bUS$9.8b41.3x61.4x4.2x
Fri, 07 Feb 2025US$676.5bUS$143.2bUS$10.3b39.2x65.4x4.7x
Sun, 05 Jan 2025US$665.5bUS$142.4bUS$10.2b43.1x65.2x4.7x
Tue, 03 Dec 2024US$672.6bUS$142.4bUS$10.2b44.9x65.7x4.7x
Thu, 31 Oct 2024US$675.3bUS$142.0bUS$8.3b38.2x81.1x4.8x
Sat, 28 Sep 2024US$750.4bUS$141.8bUS$8.5b40.1x88.3x5.3x
Mon, 26 Aug 2024US$743.2bUS$141.8bUS$8.5b37.4x87.8x5.2x
Wed, 24 Jul 2024US$690.3bUS$141.3bUS$12.3b39.7x56.1x4.9x
Fri, 21 Jun 2024US$696.9bUS$141.3bUS$12.2b38.2x57.2x4.9x
Sun, 19 May 2024US$740.9bUS$141.5bUS$12.4b38.1x59.6x5.2x
Tue, 16 Apr 2024US$711.1bUS$142.0bUS$12.8b42.3x55.6x5x
Thu, 14 Mar 2024US$753.6bUS$142.1bUS$12.8b44.9x58.7x5.3x
Sat, 10 Feb 2024US$708.4bUS$141.9bUS$12.7b39.7x55.7x5x
Mon, 08 Jan 2024US$684.7bUS$153.9bUS$14.2b36.1x48.3x4.5x
Wed, 06 Dec 2023US$651.0bUS$153.7bUS$14.0b35x46.5x4.2x
Fri, 03 Nov 2023US$568.8bUS$154.0bUS$11.1b30.4x51x3.7x
Sun, 01 Oct 2023US$672.6bUS$154.6bUS$11.2b33.3x60x4.4x
Tue, 29 Aug 2023US$712.7bUS$154.6bUS$11.2b32.9x63.6x4.6x
Thu, 27 Jul 2023US$753.5bUS$154.8bUS$11.8b30.4x63.6x4.9x
Sat, 24 Jun 2023US$690.9bUS$152.4bUS$12.5b29.3x55.3x4.5x
Price to Earnings Ratio

55.3x


Total Market Cap: US$690.9bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.3x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.4x which is lower than its 3-year average PE of 56.3x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.1% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market2.32%
Healthcare-0.64%
Life Sciences-3.21%
Clinical Research and Equipment-3.21%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ILMN IlluminaUS$164.252.6%
+US$638.5m		83.6%PE29.1x
TEM Tempus AIUS$50.563.6%
+US$312.4m		-27.9%PS6.7x
TECH Bio-TechneUS$56.033.0%
+US$253.6m		13.2%PE80.1x
VRXA VERAXA BiotechUS$21.2664.8%
+US$210.8m		104.8%n/a
TXG 10x GenomicsUS$31.753.8%
+US$147.3m		200.7%PS6.3x

Latest News

WAT
US$360.54
Waters
7D
-2.9%
1Y
5.7%
Analysis Article • 4h

Waters (WAT) Stock Could Be 8.3% Undervalued After Product Launches And FDA Clearance

Waters (WAT) is in focus after launching its BioResolve Peptide and GTxResolve Lipid columns and securing FDA 510(k) clearance for the BD BACTEC FXI Culture System, developments that expand its biopharma and diagnostics footprint. See our latest analysis for Waters. Despite the product launches and diagnostics clearance, Waters’ share price shows mixed momentum, with a 30 day share price return of 9.51% and a 90 day share price return of 22.20%, while the 1 year total shareholder return sits...
TECH
US$56.03
Bio-Techne
7D
3.0%
1Y
13.2%
RVTY
US$101.22
Revvity
7D
-2.8%
1Y
7.5%
Narrative Update • Jun 15

RVTY: Elevated Multiple And China Exit Will Test 2026 Execution

Revvity's analyst fair value estimate has shifted from $95.00 to $90.00 as analysts factor in more measured assumptions for revenue growth, profit margins, and a higher future P/E, while also weighing recent price target moves and mixed ratings across the Street. Analyst Commentary Recent Street research on Revvity shows a mix of views, with several firms adjusting ratings and price targets in different directions.
STVN
US$16.51
Stevanato Group
7D
-8.8%
1Y
-31.5%
Narrative Update • Jun 15

STVN: GLP-1 Exposure And Biologics Focus Will Support Future Earnings Power

Analysts have trimmed their price target on Stevanato Group to about $24.39 from $24.81, citing updated assumptions for the discount rate, revenue growth, profit margins, and future P/E. Recent Street research has also highlighted the company’s exposure to biologics and GLP-1 related demand.
WST
US$329.58
West Pharmaceutical Services
7D
-1.5%
1Y
51.1%
ILMN
US$164.28
Illumina
7D
1.1%
1Y
82.0%
Narrative Update • Jun 15

ILMN: Future Returns Will Hinge On Clinical Sequencing Momentum And Customer Stickiness

Narrative Update: Illumina The analyst price target underpinning this Illumina narrative has been raised from about $136 to $147, reflecting updated assumptions around customer stickiness, clinical sequencing momentum, and expectations for higher instrument and consumables spending highlighted in recent research. Analyst Commentary Recent research on Illumina reflects a mix of enthusiasm about the company’s position in sequencing markets and some ongoing caution around execution and valuation, with several major firms updating ratings and price targets.
IQV
US$179.17
IQVIA Holdings
7D
-3.8%
1Y
16.3%
Narrative Update • Jun 14

IQV: AI Initiatives And B2B Demand Will Support Earnings Reacceleration

IQVIA Holdings' implied fair value has been trimmed by about $1.65 to roughly $226.95, reflecting analysts' lower price targets around $210 in response to cautious sentiment on life science tools, even as they see early signs of recovery in areas like bioprocessing and quality assurance. Analyst Commentary Recent research points to a mixed setup for IQVIA Holdings, where cautious sentiment on life science tools is bumping up against early signs of recovery in specific end markets.
RGEN
US$131.69
Repligen
7D
1.2%
1Y
8.8%
Narrative Update • Jun 13

RGEN: Bioprocess Recovery And Training Hub Expansion Will Guide Future Performance

Repligen's analyst price target has been reset slightly lower to $142, as analysts factor in a modestly higher discount rate along with still-supportive views on bioprocessing demand and the broader life science tools recovery. Analyst Commentary Recent Street research around Repligen reflects a mixed setup, with several firms trimming price targets and a few others highlighting potential recovery in bioprocessing demand.
TEM
US$50.56
Tempus AI
7D
3.6%
1Y
-27.9%
Narrative Update • Jun 13

TEM: FDA Progress And Data Platforms Will Drive Future Oncology Demand

Tempus AI's analyst price targets have shifted lower to around $66.53, reflecting a mix of downward revisions and more cautious views on long term monetization from several firms, even as others acknowledge the company's differentiated data offering. Analyst Commentary Recent research paints a mixed picture around Tempus AI, with views split on how quickly the company can translate its differentiated data assets into predictable cash flows and what that should mean for valuation.
A
US$128.34
Agilent Technologies
7D
-5.3%
1Y
10.6%
DHR
US$181.35
Danaher
7D
-3.7%
1Y
-7.4%
TXG
US$31.75
10x Genomics
7D
3.8%
1Y
200.7%
Narrative Update • Jun 11

TXG: Multiomic Expansion And Spatial Launch Plans Will Shape Fairly Valued Outlook

Analysts have lifted their price targets on 10x Genomics by a range of $2 to $10, reflecting updated views on the stock. These revisions are now feeding into this valuation narrative and refined assumptions around discount rate, revenue growth, profit margins, and future P/E.
TMO
US$472.63
Thermo Fisher Scientific
7D
-4.3%
1Y
21.1%
Narrative Update • Jun 09

TMO: AI Tools And Proteomics Platforms Will Drive Future Upside

Thermo Fisher Scientific's updated fair value estimate has moved down from about $738 to $721 per share as analysts temper longer term revenue growth assumptions, partly reflecting recent price target cuts and more cautious views on organic growth momentum, even as they acknowledge that the company's margin profile and P/E remain supportive. Analyst Commentary Recent Street research paints a mixed picture for Thermo Fisher Scientific, with some analysts turning more cautious on near term organic growth while others highlight the stock as a core holding for exposure to life science tools.
AZTA
US$23.13
Azenta
7D
1.8%
1Y
-21.1%
Narrative Update • Jun 09

AZTA: 2026 Execution Reset And Impairment Resolution Will Support Sentiment Recovery

Analysts have reduced their average price target on Azenta by $15, reflecting updated views on the stock's risk profile and earnings power. Analyst Commentary Recent Street research on Azenta has centered on lower price targets and a reassessment of the stock's risk and earnings outlook.
CDXS
US$2.48
Codexis
7D
5.5%
1Y
5.5%
CSBR
US$6.88
Champions Oncology
7D
18.8%
1Y
-14.5%